Novel High Concentration I.V. Caffeine Rapid Reversal Agent
Address Limitations of Naloxone
and
Increase Available Treatment Options
Key Distinctions vs. Current Treatment
1. Increases duration of action: Half-Life is 6 hours
2. Novel Mechanism of action: Respiratory Stimulant
3. Limits treatment Induced Toxicity and Opioid Withdrawal Sickness
4. Does not Eliminate Pain Control in contrast to naloxone
5. Treats sedative toxidrome (Opioids + Alcohol, Barbiturates, Benzo’s)
THE 2025 EATON ENTREPRENEUR OF THE YEAR AWARD WINNER
Lyman D. Eaton II (BS 1974) and Joyce A. Eaton established the Eaton Entrepreneur of the Year Award for alumni of the College of Pharmacy who have excelled in entrepreneurial activities during their career. One recipient is chosen annually and recognized during the Dean’s Leadership and Innovation Forum. Brett Dines, RPh, MBA, is a visionary entrepreneur whose career spans the launch of groundbreaking startups to leading multi-billion-dollar divisions at Fortune 50 companies. Brett has pioneered advancements in orphan drug development as the first-ever to achieve FDA orphan drug designation for a radiopharmaceutical. As the Founder and CEO of OYE Therapeutics he recently secured a $20 million U.S. Department of Defense Award to address a series of unmet medical needs via the reformulation of a repurposed drug product.
Lyman D. Eaton II (BS 1974) and Joyce A. Eaton established the Eaton Entrepreneur of the Year Award for alumni of the College of Pharmacy who have excelled in entrepreneurial activities during their career. One recipient is chosen annually and recognized during the Dean’s Leadership and Innovation Forum. Brett Dines, RPh, MBA, is a visionary entrepreneur whose career spans the launch of groundbreaking startups to leading multi-billion-dollar divisions at Fortune 50 companies. Brett has pioneered advancements in orphan drug development as the first-ever to achieve FDA orphan drug designation for a radiopharmaceutical. As the Founder and CEO of OYE Therapeutics he recently secured a $20 million U.S. Department of Defense Award to address a series of unmet medical needs via the reformulation of a repurposed drug product.
OYE Therapeutics Selected as a Semi-Finalists in Pepperdine Graziadio’s 2024 Most Fundable Companies in the U.S.
This recognition highlights OYE’s exceptional potential and innovation in the competitive startup landscape.
Out of more than 4,000 early-stage startups from all 50 states, OYE has distinguished itself through its groundbreaking work in countering respiratory depression and reversing sedation. The selection process, conducted by Pepperdine’s Graziadio Business School, is rigorous and comprehensive, evaluating several key variables including financial projections, market opportunity, intellectual property, competitive advantage, and management-team expertise.
"We are honored to be recognized as one of the top early-stage startups in the country," said Brett Dines, CEO and Founder of OYE. "This accolade is a testament to the hard work and dedication of our entire team, as well as the transformative potential of our technology. We are committed to continuing our mission of providing clinicians with tools to save lives, especially in the ongoing struggle with Opioid Overdose."
This recognition highlights OYE’s exceptional potential and innovation in the competitive startup landscape.
Out of more than 4,000 early-stage startups from all 50 states, OYE has distinguished itself through its groundbreaking work in countering respiratory depression and reversing sedation. The selection process, conducted by Pepperdine’s Graziadio Business School, is rigorous and comprehensive, evaluating several key variables including financial projections, market opportunity, intellectual property, competitive advantage, and management-team expertise.
"We are honored to be recognized as one of the top early-stage startups in the country," said Brett Dines, CEO and Founder of OYE. "This accolade is a testament to the hard work and dedication of our entire team, as well as the transformative potential of our technology. We are committed to continuing our mission of providing clinicians with tools to save lives, especially in the ongoing struggle with Opioid Overdose."
OYE invited to participate in ACTTION Conference February, 2024
OYE Therapeutics, Inc. to Participate at ACTTION Consortium Meeting Co-Chaired by Dr. Ken Solt, the Director of Translational Research and Innovation in Anesthesia Critical Care and Pain Medicine at Harvard Medical School
Convened by Dr. Solt, the meeting aims to bring together a diverse group of experts, spanning anesthesiology, neurology, and consciousness research. The goal is to foster collaborative discussions and initiatives that will drive innovation in anesthetic agents and modulation.
OYE Therapeutics, Inc. to Participate at ACTTION Consortium Meeting Co-Chaired by Dr. Ken Solt, the Director of Translational Research and Innovation in Anesthesia Critical Care and Pain Medicine at Harvard Medical School
BIO (Biotechnology Innovation Organization) Investor Forum October, 2023
BIO (Biotechnology Innovation Organization) Investor Forum October, 2023
OYE Therapeutics CEO, Brett Dines, will share a company update with investors and industry analysts at the upcoming BIO Investor Forum. The presentation will spotlight strides made by the company over recent quarters, with a primary focus on OYE's novel formulation of high-concentration caffeine. This advancement marks a significant leap towards the development of the world's first Rapid Active Reversal Agent for general anesthesia, poised to redefine global standards in perioperative care. The agent both causes emergence to occur and shortens the time period. This is in stark contrast to passive emergence, the current process which has remained fundamentally unchanged since the advent of anesthetic agents.
OYE Therapeutics CEO, Brett Dines, will share a company update with investors and industry analysts at the upcoming BIO Investor Forum. The presentation will spotlight strides made by the company over recent quarters, with a primary focus on OYE's novel formulation of high-concentration caffeine. This advancement marks a significant leap towards the development of the world's first Rapid Active Reversal Agent for general anesthesia, poised to redefine global standards in perioperative care. The agent both causes emergence to occur and shortens the time period. This is in stark contrast to passive emergence, the current process which has remained fundamentally unchanged since the advent of anesthetic agents.
American Society of Anesthesiologists Annual Meeting October, 2023
American Society of Anesthesiologists Annual Meeting October, 2023
OYE Therapeutics, Inc., a clinical-stage drug development company, came away very encouraged by the presentations at the American Society of Anesthesiology Annual Meeting in San Francisco from October 13 to October 17, 2023. Several compelling research presentations highlighted the growing body of evidence supporting the efficacy of caffeine administration in various perioperative applications.
2023 BIO CEO & Investor Conference
February, 2023
Taking its act on the road, OYE Therapeutics will present in New York at one of the largest investor conferences where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry through partnering, company presentations, and educational sessions on therapeutic advancements, market outlook, and policy priorities.
Taking its act on the road, OYE Therapeutics will present in New York at one of the largest investor conferences where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry through partnering, company presentations, and educational sessions on therapeutic advancements, market outlook, and policy priorities.
OYE Therapeutics will present at the BioTech Showcase in San Francisco from January 9-11. 2023.
OYE Therapeutics will present at the BioTech Showcase in San Francisco from January 9-11. 2023. Aimed at highlighting industry innovators, Biotech Showcase and its family of dedicated showcases grant you access to the life science ecosystem during the busiest week in healthcare. OYE's presentation will focus on the company pipeline, with a specific focus on their lead clinical program, developing the first Active Reversal Agent for General Anesthesia
OYE Therapeutics will present at the BioTech Showcase in San Francisco from January 9-11. 2023. Aimed at highlighting industry innovators, Biotech Showcase and its family of dedicated showcases grant you access to the life science ecosystem during the busiest week in healthcare. OYE's presentation will focus on the company pipeline, with a specific focus on their lead clinical program, developing the first Active Reversal Agent for General Anesthesia
ABL, Adaptive Business Leaders, Bay Area have named O.Y.E. Therapeutics as one of its “Innovators in Healthcare” for 2021
Brett Dines, O.Y.E.’s CEO, was one of three presenters/awardees who spoke at ABL’s 24th Innovations in Healthcare ~ Bay Area Edition on December 8, 2021. According to ABL’s announcement regarding the event, “This year’s “Innovators in Healthcare” saw opportunities where others saw only the problems.” As for O.Y.E., “Brett Dines, CEO of OYE Therapeutics, knew the stats: “delayed emergence” from the coma-like state created by anesthesia contributes to over 32,000 deaths, 2.4 million extra days of post-surgical hospitalization, and $9.3 billion in added OR expenses each year. The good news is that Brett’s team is working on the solution.” Brett’s presentation focused not only on delayed emergence, but also the other clinical programs currently being researched at the pharmaceutical development company. In keeping with the times, Brett’s presentation was virtual, as was the entire conference. Other “attendees” included Robert Funari, Chairperson of O.Y.E.’s Board, who was invited to introduce Mr. Dines. Mr. Funari concurred with ABL as to the innovation he witnessed from his current position at OYE as well as from his long-standing professional association with the CEO.
O.Y.E. is located at the Purdue Research Park of Northwest Indiana. They focus on identifying “gaps in medical care” and filling those gaps through innovative therapeutic solutions. Their goals are to directly save lives while improving the quality of care for all patients. Michael Hicks, COO, said, “O.Y.E. is built on Brett Dine’s vision. A unique opportunity presented itself and Brett recognized the ability to make a difference in healthcare. That one decision - to move forward because it would help - spawned the philosophy that drives all of O.Y.E.’s goals, both operational and aspirational.”
Brett Dines, O.Y.E.’s CEO, was one of three presenters/awardees who spoke at ABL’s 24th Innovations in Healthcare ~ Bay Area Edition on December 8, 2021. According to ABL’s announcement regarding the event, “This year’s “Innovators in Healthcare” saw opportunities where others saw only the problems.” As for O.Y.E., “Brett Dines, CEO of OYE Therapeutics, knew the stats: “delayed emergence” from the coma-like state created by anesthesia contributes to over 32,000 deaths, 2.4 million extra days of post-surgical hospitalization, and $9.3 billion in added OR expenses each year. The good news is that Brett’s team is working on the solution.” Brett’s presentation focused not only on delayed emergence, but also the other clinical programs currently being researched at the pharmaceutical development company. In keeping with the times, Brett’s presentation was virtual, as was the entire conference. Other “attendees” included Robert Funari, Chairperson of O.Y.E.’s Board, who was invited to introduce Mr. Dines. Mr. Funari concurred with ABL as to the innovation he witnessed from his current position at OYE as well as from his long-standing professional association with the CEO.
O.Y.E. Therapeutics announces successful pre-IND meeting with FDA
O.Y.E. Therapeutics, a clinical-stage pharmaceutical development company with a drug targeted at expediting emergence from anesthesia, has announced a successful pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration.
A pre-IND meeting provides an opportunity for a drug development company and the FDA to discuss the drug's development plan and to obtain the agency's guidance for clinical studies of the company's new drug candidate.
"We are grateful for the guidance from the FDA as we move into our next phase of research," said Brett Dines, O.Y.E. CEO. "They were helpful as to what they wished to see regarding the safety profile of our product. They also offered feedback that our trial design would be effective at demonstrating efficacy in their eyes.
O.Y.E. Therapeutics, a clinical-stage pharmaceutical development company with a drug targeted at expediting emergence from anesthesia, has announced a successful pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration.
A pre-IND meeting provides an opportunity for a drug development company and the FDA to discuss the drug's development plan and to obtain the agency's guidance for clinical studies of the company's new drug candidate.
"We are grateful for the guidance from the FDA as we move into our next phase of research," said Brett Dines, O.Y.E. CEO. "They were helpful as to what they wished to see regarding the safety profile of our product. They also offered feedback that our trial design would be effective at demonstrating efficacy in their eyes.
Research agreement focuses
on battlefield injuries
OYE Therapeutics Inc., a Purdue University-affiliated company, is working to reduce the mortality and morbidity resulting from injuries on the battlefield through the development of new life-saving strategies.
OYE is located in the Purdue Technology Center in the Purdue Research Park of Northwest Indiana.
The company has entered into a Cooperative Research and Development Agreement (CRADA) with the Uniformed Services University of the Health Sciences (USU), an institution of higher learning within the U.S. Department of Defense and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF).
The partnership includes researching the effectiveness of OYE-002 to enhance acute pain control at the point-of-injury, cognitive processing, psychomotor resilience and mission capabilities.
